Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa M Berrien-Elliott

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Missouri Medicine|May 13, 2026
Allogenic Memory-Like Natural Killer Cell TherapyAlaa M Khalifa, Melissa M Berrien-Elliott
Current Opinion in Organ Transplantation|September 29, 2015
Improving natural killer cell cancer immunotherapyMelissa M Berrien-Elliott, Rizwan Romee, Todd A Fehniger
Blood|November 23, 2022
Allogeneic natural killer cell therapyMelissa M Berrien-Elliott, Miriam T Jacobs, Todd A Fehniger
Journal of Innate Immunity|May 1, 2015
Human Cytokine-Induced Memory-Like Natural Killer CellsMelissa M Berrien-Elliott, Julia A Wagner, Todd A Fehniger
Seminars in Hematology|December 1, 2020
Memory-like natural killer cells for cancer immunotherapyMargery Gang, Pamela Wong, Melissa M Berrien-Elliott, et al.
STAR Protocols|January 25, 2021
Flow cytometry-based <i>ex vivo</i> murine NK cell cytotoxicity assayPamela Wong, Julia A Wagner, Melissa M Berrien-Elliott, et al.
Current Opinion in Immunology|October 11, 2025
Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignanciesSimone A Minnie, Melissa M Berrien-Elliott, Melody Smith, et al.
Immunological Investigations|March 7, 2013
CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptorStephanie R Jackson, Melissa M Berrien-Elliott, Jennifer M Meyer, et al.
Journal of Leukocyte Biology|May 15, 2014
Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional toleranceStephanie R Jackson, Jinyun Yuan, Melissa M Berrien-Elliott, et al.
Cancer Immunology Research|December 18, 2014
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cellsMelissa M Berrien-Elliott, Jinyun Yuan, Lauryn E Swier, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Missouri Medicine|May 13, 2026
Allogenic Memory-Like Natural Killer Cell TherapyAlaa M Khalifa, Melissa M Berrien-Elliott
Current Opinion in Organ Transplantation|September 29, 2015
Improving natural killer cell cancer immunotherapyMelissa M Berrien-Elliott, Rizwan Romee, Todd A Fehniger
Blood|November 23, 2022
Allogeneic natural killer cell therapyMelissa M Berrien-Elliott, Miriam T Jacobs, Todd A Fehniger
Journal of Innate Immunity|May 1, 2015
Human Cytokine-Induced Memory-Like Natural Killer CellsMelissa M Berrien-Elliott, Julia A Wagner, Todd A Fehniger
Seminars in Hematology|December 1, 2020
Memory-like natural killer cells for cancer immunotherapyMargery Gang, Pamela Wong, Melissa M Berrien-Elliott, et al.
STAR Protocols|January 25, 2021
Flow cytometry-based <i>ex vivo</i> murine NK cell cytotoxicity assayPamela Wong, Julia A Wagner, Melissa M Berrien-Elliott, et al.
Current Opinion in Immunology|October 11, 2025
Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignanciesSimone A Minnie, Melissa M Berrien-Elliott, Melody Smith, et al.
Immunological Investigations|March 7, 2013
CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptorStephanie R Jackson, Melissa M Berrien-Elliott, Jennifer M Meyer, et al.
Journal of Leukocyte Biology|May 15, 2014
Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional toleranceStephanie R Jackson, Jinyun Yuan, Melissa M Berrien-Elliott, et al.
Cancer Immunology Research|December 18, 2014
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cellsMelissa M Berrien-Elliott, Jinyun Yuan, Lauryn E Swier, et al.
Pageof 5